Bad Haircuts: 2005's Biotech IPOs--Getting Out at Any Price?

The haircuts suffered by 2005's biotech IPOs are further proof that while the appetite for biotech offerings exists, public investors are demanding a better likelihood of post-market upside.

The reduced offering prices that have become commonplace so far this year are unlikely to be signs that the public financing window is closing. (See Exhibit 1.) Instead, the haircuts suffered nearly across the board—and both in Europe and the US—in 2005 are more likely further proof that, while the appetite for biotech offerings exists, public investors are demanding a better likelihood of post-market upside. Often they're getting it, but not always.

In the US, anyway, those firms with the biggest haircuts were still trading down in the aftermarket. Favrille Inc. ...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.